Morgan Stanley downgraded Lazard from Equal-Weight to Underweight and set a new price target of $33.00 from $56.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/7/2025 | $56.00 → $33.00 | Equal-Weight → Underweight | Morgan Stanley |
| 1/3/2025 | Outperform → Peer Perform | Wolfe Research | |
| 12/20/2024 | $65.00 → $57.00 | Outperform → Mkt Perform | Keefe Bruyette |
| 12/9/2024 | $60.00 → $63.00 | Overweight → Equal-Weight | Morgan Stanley |
| 9/12/2024 | $51.00 | Equal Weight | Wells Fargo |
| 1/29/2024 | $51.00 | Outperform | Keefe Bruyette |
| 1/3/2024 | $42.00 | Peer Perform → Outperform | Wolfe Research |
| 9/19/2023 | $37.00 → $32.00 | Neutral → Sell | Goldman |
Lazard Global Total Return and Income Fund, Inc. (the "Fund") (NYSE:LGI) is confirming today, pursuant to its Managed Distribution Policy, as previously authorized by its Board of Directors, a monthly distribution of $0.14646 per share on the Fund's outstanding common stock. The distribution is payable on July 22, 2025 to shareholders of record on July 10, 2025. The ex-dividend date is July 10, 2025. The Fund will pay a previously declared distribution today, June 24, 2025. The following table sets forth the estimated amounts of the current distribution and the cumulative distributions paid, including today's distribution, from the following sources: net investment income, net realized ca
Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, announces the appointment of Ajay Dhankhar, PhD, as Chief Corporate Development & Strategy Officer, effective today. Ajay will report to Chief Executive Officer Deepak Nath and join the Smith+Nephew Executive Committee. As both a senior management consultant and investment banker, Ajay has advised CEOs and Boards at some of the world's leading healthcare companies, helping deliver substantial shareholder value. Ajay's experience includes 25 years with McKinsey & Company where he was a Senior Partner and held multiple leadership roles including Global Head of Strategy across all industries, Global Head of Strategy
Renewables Remain Competitive, as Utility-Scale Solar and Onshore Wind Remain Most Cost-Effective Forms of New-Build Energy Generation The Tightening of Capacity Markets Has Led to a Resurgence in New-Build Gas Generation Projects, Despite Higher Levelized Costs of Energy and Commodity Price Exposure Lazard Inc. (NYSE:LAZ) is proud to announce the release of the 18th edition of its Levelized Cost of Energy+ (LCOE+) report, a widely-cited, annual analysis that provides insights into the cost competitiveness of various energy generation technologies. The report explores key aspects of energy generation, energy storage, and system-level considerations while reflecting on developments over
4 - Lazard, Inc. (0001311370) (Issuer)
4 - Lazard, Inc. (0001311370) (Issuer)
4 - Lazard, Inc. (0001311370) (Issuer)
Morgan Stanley downgraded Lazard from Equal-Weight to Underweight and set a new price target of $33.00 from $56.00 previously
Wolfe Research downgraded Lazard from Outperform to Peer Perform
Keefe Bruyette downgraded Lazard from Outperform to Mkt Perform and set a new price target of $57.00 from $65.00 previously
SCHEDULE 13G - Lazard, Inc. (0001311370) (Subject)
8-K - Lazard, Inc. (0001311370) (Filer)
SCHEDULE 13G/A - Lazard, Inc. (0001311370) (Subject)